^
    1d
    A Phase III Study for 601 Versus Ranibizumab in Patients With Vision Loss (clinicaltrials.gov)
    P3, N=351, Completed, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Recruiting --> Completed
    Trial completion
    |
    Lucentis (ranibizumab)
    1d
    Targeting DDOST improves the efficacy of lenvatinib and immunotherapy in hepatocellular carcinoma. (PubMed, Exp Mol Med)
    Furthermore, the OST inhibitor NGI-1 and NGI-1-loaded nanoparticles exerted potent antitumor effects and further augmented the efficacy of lenvatinib and immunotherapy. These findings highlight DDOST as a promising therapeutic target to improve treatment outcomes in HCC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)
    |
    Lenvima (lenvatinib)
    1d
    Efficacy and safety of Atezolizumab plus Bevacizumab and Lenvatinib as first-line systemic therapies for hepatocellular carcinoma: A real-world study. (PubMed, PLoS One)
    In conclusion, the study demonstrates that ATEZO/BEV significantly improves OS compared to LEN in patients with unresectable HCC, despite similar PFS, ORR, and DCR. Both treatments have comparable safety profiles.
    Retrospective data • Journal • Real-world evidence
    |
    AFP (Alpha-fetoprotein)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Lenvima (lenvatinib)
    2d
    Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma (clinicaltrials.gov)
    P2, N=36, Recruiting, Sun Yat-sen University | Trial completion date: Nov 2025 --> Dec 2027 | Trial primary completion date: Nov 2024 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    Tyvyt (sintilimab) • capecitabine • Sulanda (surufatinib)
    2d
    Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012) (clinicaltrials.gov)
    P3, N=480, Active, not recruiting, Merck Sharp & Dohme LLC | Trial primary completion date: Jun 2028 --> Aug 2025 | Trial completion date: Dec 2029 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)
    3d
    Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer (clinicaltrials.gov)
    P2, N=62, Active, not recruiting, University of Southern California | Trial primary completion date: Dec 2025 --> Jun 2026
    Trial primary completion date • Checkpoint inhibition
    |
    PD-L1 (Programmed death ligand 1)
    |
    Inlyta (axitinib) • ivuxolimab (PF-04518600)
    3d
    Fruquintinib Combined With TAS-102 Versus Bevacizumab Combined With TAS-102 for Advanced Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=292, Not yet recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    New P2 trial
    |
    Avastin (bevacizumab) • Fruzaqla (fruquintinib) • Lonsurf (trifluridine/tipiracil)
    4d
    Dapagliflozin alleviates sunitinib-induced cardiotoxicity through AMPKα-PPARα axis and enhances the sensitivity of renal cell carcinoma to sunitinib. (PubMed, BMC Med)
    Our results demonstrate that dapagliflozin not only enhances the antitumor efficacy of sunitinib against renal cell carcinoma but also alleviates sunitinib-induced cardiac toxicity in mice via modulation of the AMPKα-PPARα axis.
    Journal
    |
    PPARA (Peroxisome Proliferator Activated Receptor Alpha)
    |
    sunitinib
    4d
    Multimodal Deep Learning for Postoperative Liver Cancer Risk Stratification and Intervention (clinicaltrials.gov)
    P1/2, N=144, Recruiting, Tongji Hospital
    New P1/2 trial
    |
    5-fluorouracil • Lenvima (lenvatinib) • oxaliplatin
    4d
    PD-1/ PD-L1 bispecific antibody IBI318 combined with lenvatinib in advanced non-small cell lung cancer with acquired resistance to immune checkpoint inhibitors: a phase II trial. (PubMed, Nat Commun)
    Further, we performed a post-hoc exploratory analysis and developed an XGBoost model (scPro-X) using scRNA-seq data from pre-treatment tumor samples to predict 12-week ORR identified CD4_Tfh_CXCL13 and CD8_Tex_CTLA4 as potential biomarkers predictive of response. These findings demonstrate that IBI318 plus lenvatinib exhibit promising clinical activity and a manageable safety profile in patients with advanced NSCLC.
    P2 data • Preclinical • Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1)
    |
    Lenvima (lenvatinib) • reozalimab (IBI318)
    5d
    CLEC4G Reverses Lenvatinib Resistance in Hepatocellular Carcinoma by Suppressing PD-1 Expression via the Wnt/β-Catenin Pathway. (PubMed, Int J Genomics)
    Silencing CLEC4G could reverse the effect of LiCl on PLC/PRF/5-R. CLEC4G modulates the PD-1 expression of HCC cells through the Wnt/β-catenin pathway, thereby reversing the resistance to Lenva.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1)
    |
    Lenvima (lenvatinib)
    7d
    - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases (clinicaltrials.gov)
    P2, N=140, Recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Not yet recruiting --> Recruiting | Initiation date: Apr 2025 --> Oct 2025
    Enrollment open • Trial initiation date • Mismatch repair • pMMR
    |
    BRAF (B-raf proto-oncogene)
    |
    Avastin (bevacizumab) • Tevimbra (tislelizumab-jsgr) • Fruzaqla (fruquintinib) • Lonsurf (trifluridine/tipiracil)